Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302

BACKGROUND: Hypoxic niches in solid tumors harbor therapy-resistant cells. Hypoxia-activated prodrugs (HAPs) have been designed to overcome this resistance and, to date, have begun to show clinical efficacy. However, clinical HAPs activity could be improved. In this study, we sought to identify non-...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Cancer Metab
المؤلفون الرئيسيون: Wojtkowiak, Jonathan W, Cornnell, Heather C, Matsumoto, Shingo, Saito, Keita, Takakusagi, Yoichi, Dutta, Prasanta, Kim, Munju, Zhang, Xiaomeng, Leos, Rafael, Bailey, Kate M, Martinez, Gary, Lloyd, Mark C, Weber, Craig, Mitchell, James B, Lynch, Ronald M, Baker, Amanda F, Gatenby, Robert A, Rejniak, Katarzyna A, Hart, Charles, Krishna, Murali C, Gillies, Robert J
التنسيق: Artigo
اللغة:Inglês
منشور في: BioMed Central 2015
الموضوعات:
Research
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4310189/
https://ncbi.nlm.nih.gov/pubmed/25635223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40170-014-0026-z
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة